Commentary: non-alcoholic steatohepatitis-finding and minding the fire behind the smoke
- PMID: 31850574
- DOI: 10.1111/apt.15565
Commentary: non-alcoholic steatohepatitis-finding and minding the fire behind the smoke
Comment on
-
Adipokines and cytokines in non-alcoholic fatty liver disease.Aliment Pharmacol Ther. 2008 Mar 1;27(5):412-21. doi: 10.1111/j.1365-2036.2007.03586.x. Epub 2007 Dec 10. Aliment Pharmacol Ther. 2008. PMID: 18081738
References
REFERENCES
-
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
-
- Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874-1882.
-
- Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51:371-379.
-
- Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67:1265-1273.
-
- Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011;121:2111-2117.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical